Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ranibizumab with Phacoemulsification for Mild NPDR
NCT05386160Phase 4Unknown
- Sponsor
- Ruijin Hospital
- Start
- Jul 2022
- Primary completion
- Mar 2023
- Modality
- Antibody Fragments, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 4 trial of ranibizumab in diabetic retinopathy (DR), sponsored by Ruijin Hospital. Status: unknown.
02
Drugs
ranibizumab
03
Conditions
diabetic retinopathy (DR)
Beyond the preview
Go deeper on NCT05386160.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05386160.